121 research outputs found
Twierdza Kłodzko Pomnikiem Historii? Rola ochrony zabytków w kontekście i wobec polityki
Kłodzko Fortress - an undisputed witness of the stormy Silesian wars between the two powers: Austria and Prussia, whose course changed the map of 18th- century Europe, but above all the building which is a unique example of modern military architecture in Europe, where the architectural solutions of several fortification schools intersect, preserved to this day and making the Kłodzko fortress a kind of encyclopedia of fortifications - remains outside the list of monuments recognized as Monuments of History. The efforts undertaken in 2009 to include the fortress on this list of prestigious monuments did not bring the expected result, and the past decade has provided many valuable conclusions on the role and scope of protection of monuments in relation to both local and central politics. This article is an attempt at a synthetic presentation of the case of the Kłodzko Fortress in connection with a renewed attempt to obtain the title of a Monument of History. It is also an echo of the voices focusing on the strictly Polish heritage that emerged during the conference Monuments of History - protection, management, promotion.
Twierdza Kłodzko – niekwestionowany świadek burzliwych wojen śląskich między dwoma mocarstwami: cesarską Austrią i rosnącymi w silę Prusami, których przebieg zmienił mapę XVIIIwiecznej Europy, ale przede wszystkim obiekt stanowiący wyjątkowy w skali Europy przykład nowożytnej architectura militaris, gdzie krzyżują się rozwiązania architektoniczne kilku szkół fortyfikacyjnych, zachowane do dziś i czyniące z kłodzkiej twierdzy swoistą encyklopedię fortyfikacji – pozostaje poza listą zabytków uznanych za Pomniki Historii.
Podjęte w 2009 r. starania o wpisanie twierdzy na tę listę prestiżowych zabytków nie przyniosły spodziewanego rezultatu, a miniona dekada dostarcza wielu cennych wniosków na temat roli i zakresu ochrony zabytków wobec zarówno lokalnej, jak i centralnej polityki.
Niniejszy artykuł stanowi próbę syntetycznej prezentacji przypadku Twierdzy Kłodzko w związku z ponownie podjętą próbą uzyskania tytułu Pomnika Historii. Jest również echem głosów koncentrujących się na dziedzictwie stricte polskim, wybrzmiałych podczas konferencji Pomniki Historii – ochrona, zarządzanie, promocja.
 
CD4+ T Cell Regulation of CD25 Expression Controls Development of Short-Lived Effector CD8+ T Cells in Primary and Secondary Responses
Both CD4(+) T cell help and IL-2 have been postulated to program activated CD8(+) T cells for memory cell development. However, the linkage between these two signals has not been well elucidated. Here we have studied effector and memory CD8(+) T cell differentiation following infection with three pathogens (Listeria monocytogenes, vesicular stomatitis virus, and vaccinia virus) in the absence of both CD4(+) T cells and IL-2 signaling. We found that expression of CD25 on antigen-specific CD8(+) T cells peaked 3-4 days after initial priming and was dependent on CD4(+) T cell help, likely through a CD28:CD80/86 mediated pathway. CD4(+) T cell or CD25-deficiency led to normal early effector CD8(+) T cell differentiation, but a subsequent lack of accumulation of CD8(+) T cells resulting in overall decreased memory cell generation. Interestingly, in both primary and recall responses KLRG1(high) CD127(low) short-lived effector cells were drastically diminished in the absence of IL-2 signaling, although memory precursors remained intact. In contrast to previous reports, upon secondary antigen encounter CD25-deficient CD8(+) T cells were capable of undergoing robust expansion, but short-lived effector development was again impaired. Thus, these results demonstrated that CD4(+) T cell help and IL-2 signaling were linked via CD25 up-regulation, which controls the expansion and differentiation of antigen-specific effector CD8(+) T cells, rather than programming memory cell traits
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
The in vivo requirements for human natural killer (NK) cell development and differentiation into cytotoxic effectors expressing inhibitory receptors for self–major histocompatability complex class I (MHC-I; killer Ig-like receptors [KIRs]) remain undefined. Here, we dissect the role of interleukin (IL)-15 in human NK cell development using Rag2−/−γc−/− mice transplanted with human hematopoietic stem cells. Human NK cell reconstitution was intrinsically low in this model because of the poor reactivity to mouse IL-15. Although exogenous human IL-15 (hIL-15) alone made little improvement, IL-15 coupled to IL-15 receptor α (IL-15Rα) significantly augmented human NK cells. IL-15–IL-15Rα complexes induced extensive NK cell proliferation and differentiation, resulting in accumulation of CD16+KIR+ NK cells, which was not uniquely dependent on enhanced survival or preferential responsiveness of this subset to IL-15. Human NK cell differentiation in vivo required hIL-15 and progressed in a linear fashion from CD56hiCD16−KIR− to CD56loCD16+KIR−, and finally to CD56loCD16+KIR+. These data provide the first evidence that IL-15 trans-presentation regulates human NK cell homeostasis. Use of hIL-15 receptor agonists generates a robust humanized immune system model to study human NK cells in vivo. IL-15 receptor agonists may provide therapeutic tools to improve NK cell reconstitution after bone marrow transplants, enhance graft versus leukemia effects, and increase the pool of IL-15–responsive cells during immunotherapy strategies
Engulfing tumors with synthetic extracellular matrices for cancer
available in PMC 2010 June 1.Local immunotherapies are under investigation for the treatment of unresectable tumors and sites of solid tumor resection to prevent local recurrence. Successful local therapy could also theoretically elicit systemic immune responses against cancer. Here we explored the delivery of therapeutic dendritic cells (DCs), cytokines, or other immunostimulatory factors to tumors via the use of ‘self-gelling’ hydrogels based on the polysaccharide alginate, injected peritumorally around established melanoma lesions. Peritumoral injection of alginate matrices loaded with DCs and/or an interleukin-15 superagonist (IL-15SA) around 14-day established ova-expressing B16F0 murine melanoma tumors promoted immune cell accumulation in the peritumoral matrix, and matrix infiltration correlated with tumor infiltration by leukocytes. Single injections of IL-15SA-carrying gels concentrated the cytokine in the tumor site ∼40-fold compared to systemic injection and enabled a majority of treated animals to suppress tumor growth for a week or more. Further, we found that single injections of alginate matrices loaded with IL-15SA and the Toll-like receptor ligand CpG or two injections of gels carrying IL-15SA alone could elicit comparable anti-tumor activity without the need for exogenous DCs. Thus, injectable alginate gels offer an attractive platform for local tumor immunotherapy, and facilitate combinatorial treatments designed to promote immune responses locally at a tumor site while limiting systemic exposure to potent immunomodulatory factors.United States. Defense Advanced Research Projects Agency ( (contract # W81XWH-04-C-0139)National Institutes of Health (U.S.) (NIH Grant EB007280)National Institutes of Health (U.S.) (NIH Grant U54-CA126515)National Institutes of Health (U.S.) (NIH Grant U54-CA112967)National Science Foundation (U.S.) (award 0348259
Interleukin-15 Treatment Induces Weight Loss Independent of Lymphocytes
Obesity is a chronic inflammatory condition characterized by activation and infiltration of proinflammatory immune cells and a dysregulated production of proinflammatory cytokines. While known as a key regulator of immune natural killer (NK) cell function and development, we have recently demonstrated that reduced expression of the cytokine Interleukin-15 (IL-15) is closely linked with increased body weight and adiposity in mice and humans. Previously, we and others have shown that obese individuals have lower circulating levels of IL-15 and NK cells. Lean IL-15 overexpressing (IL-15 tg) mice had an accumulation in adipose NK cells compared to wildtype and NK cell deficient obese IL-15−/− mice. Since IL-15 induces weight loss in IL-15−/− and diet induced obese mice and has effects on various lymphocytes, the aim of this paper was to determine if lymphocytes, particularly NK cells, play a role in IL-15 mediated weight loss. Acute IL-15 treatment resulted in an increased accumulation of NK, NKT, and CD3+ T cells in adipose tissue of B6 mice. Mice depleted of NK and NKT cells had similar weight loss comparable to controls treated with IL-15. Finally, IL-15 treatment induces significant weight loss in lymphocyte deficient RAG2−/−γc−/− mice independent of food intake. Fat pad cross-sections show decreased pad size with cytokine treatment is due to adipocyte shrinkage. These results clearly suggest that IL-15 mediates weight loss independent of lymphocytes
Development of a Quantitative Bead Capture Assay for Soluble IL-7 Receptor Alpha in Human Plasma
IL-7 is an essential cytokine in T-cell development and homeostasis. It binds to the IL-7R receptor, a complex of the IL-7Rα (CD127) and common γ (CD132) chains. There is significant interest in evaluating the expression of CD127 on human T-cells as it often decreased in medical conditions leading to lymphopenia. Previous reports showed the usefulness of CD127 as a prognostic marker in viral infections such as HIV, CMV, EBV and HCV. A soluble CD127 (sCD127) is released in plasma and may contribute to disease pathogenesis through its control on IL-7 activities. Measuring sCD127 is important to define its role and may complement existing markers used in lymphopenic disease management. We describe a new quantitative assay for the measurement of sCD127 in plasma and report sCD127 concentrations in healthy adults.We developed a quantitative bead-based sCD127 capture assay. Polyclonal CD127-specific antibodies were chosen for capture and a biotinylated monoclonal anti-CD127 antibody was selected for detection. The assay can detect native sCD127 and recombinant sCD127 which served as the calibrator. The analytical performance of the assay was characterized and the concentration and stability of plasma sCD127 in healthy adults was determined. The assay's range was 3.2–1000 ng/mL. The concentration of plasma sCD127 was 164±104 ng/mL with over a log variation between subjects. Individual sCD127 concentrations remained stable when measured serially during a period of up to one year.This is the first report on the quantification of plasma sCD127 in a population of healthy adults. Soluble CD127 plasma concentrations remained stable over time in a given individual and sCD127 immunoreactivity was resistant to repeated freeze-thaw cycles. This quantitative sCD127 assay is a valuable tool for defining the potential role of sCD127 in lymphopenic diseases
IL-15 Participates in the Respiratory Innate Immune Response to Influenza Virus Infection
Following influenza infection, natural killer (NK) cells function as interim effectors by suppressing viral replication until CD8 T cells are activated, proliferate, and are mobilized within the respiratory tract. Thus, NK cells are an important first line of defense against influenza virus. Here, in a murine model of influenza, we show that virally-induced IL-15 facilitates the trafficking of NK cells into the lung airways. Blocking IL-15 delays NK cell entry to the site of infection and results in a disregulated control of early viral replication. By the same principle, viral control by NK cells can be therapeutically enhanced via intranasal administration of exogenous IL-15 in the early days post influenza infection. In addition to controlling early viral replication, this IL-15-induced mobilization of NK cells to the lung airways has important downstream consequences on adaptive responses. Primarily, depletion of responding NK1.1+ NK cells is associated with reduced immigration of influenza-specific CD8 T cells to the site of infection. Together this work suggests that local deposits of IL-15 in the lung airways regulate the coordinated innate and adaptive immune responses to influenza infection and may represent an important point of immune intervention
Selective Reduction of Post-Selection CD8 Thymocyte Proliferation in IL-15Rα Deficient Mice
Peripheral CD8+ T cells are defective in both IL-15 and IL-15Rα knock-out (KO) mice; however, whether IL-15/IL-15Rα deficiency has a similar effect on CD8 single-positive (SP) thymocytes remains unclear. In this study, we investigated whether the absence of IL-15 transpresentation in IL-15Rα KO mice results in a defect in thymic CD8 single positive (SP) TCRhi thymocytes. Comparison of CD8SP TCRhi thymocytes from IL-15Rα KO mice with their wild type (WT) counterparts by flow cytometry showed a significant reduction in the percentage of CD69− CD8SP TCRhi thymocytes, which represent thymic premigrants. In addition, analysis of in vivo 5-bromo-2-deoxyuridine (BrdU) incorporation demonstrated that premigrant expansion of CD8SP TCRhi thymocytes was reduced in IL-15Rα KO mice. The presence of IL-15 transpresentation-dependent expansion in CD8SP TCRhi thymocytes was assessed by culturing total thymocytes in IL-15Rα-Fc fusion protein-pre-bound plates that were pre-incubated with IL-15 to mimic IL-15 transpresentation in vitro. The results demonstrated that CD8SP thymocytes selectively outgrew other thymic subsets. The contribution of the newly divided CD8SP thymocytes to the peripheral CD8+ T cell pool was examined using double labeling with intrathymically injected FITC and intravenously injected BrdU. A marked decrease in FITC+ BrdU+ CD8+ T cells was observed in the IL-15Rα KO lymph nodes. Through these experiments, we identified an IL-15 transpresentation-dependent proliferation process selective for the mature CD8SP premigrant subpopulation. Importantly, this process may contribute to the maintenance of the normal peripheral CD8+ T cell pool
G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses
BACKGROUND: Administration of recombinant G-CSF following cytoreductive therapy enhances the recovery of myeloid cells, minimizing the risk of opportunistic infection. Free G-CSF, however, is expensive, exhibits a short half-life, and has poor biological activity in vivo. METHODS: We evaluated whether the biological activity of G-CSF could be improved by pre-association with anti-G-CSF mAb prior to injection into mice. RESULTS: We find that the efficacy of G-CSF therapy can be enhanced more than 100-fold by pre-association of G-CSF with an anti-G-CSF monoclonal antibody (mAb). Compared with G-CSF alone, administration of G-CSF/anti-G-CSF mAb complexes induced the potent expansion of CD11b(+)Gr-1(+) myeloid cells in mice with or without concomitant cytoreductive treatment including radiation or chemotherapy. Despite driving the dramatic expansion of myeloid cells, in vivo antigen-specific CD8(+) T cell immune responses were not compromised. Furthermore, injection of G-CSF/anti-G-CSF mAb complexes heightened protective immunity to bacterial infection. As a measure of clinical value, we also found that antibody complexes improved G-CSF biological activity much more significantly than pegylation. CONCLUSIONS: Our findings provide the first evidence that antibody cytokine complexes can effectively expand myeloid cells, and furthermore, that G-CSF/anti-G-CSF mAb complexes may provide an improved method for the administration of recombinant G-CSF
Investigating the biology of IL-15 and IL-15/IL-15Ralpha
IL-15 plays a multifaceted role in the development and maintenance of the immune system and is an attractive therapeutic target for the treatment of tumors and intracellular infections, such as viruses. The current data illustrate that IL-15 is not secreted, but rather associates intracellularly with IL-15Rα and is transpresented on a cell\u27s surface to apposing cells that minimally express the shared IL-2Rβγ. This mechanism of action, along with other regulatory factors, has made it difficult to detect IL-15 protein and has important implications when utilizing IL-15 as a therapeutic. The work presented in this thesis has three main points. Firstly, we illustrate that administering IL-15 precomplexed to sIL-15Rα enhances IL-15 activity in vivo by increasing IL-15 half-life and bioavailability, as well as forcing IL-15 transpresentation. Interestingly, IL-15/sIL-15Rα treatment can stimulate tumor rejection better than IL-15 alone. Secondly, we also demonstrate that although naïve CD8 T cells appear nonresponsive to IL-15 alone in vivo they can respond vigorously to IL-15/sIL-15Rα in a MHC class I dependent manner, proliferating and acquiring effector function. A naïve CD8 T cell\u27s degree of responsiveness to IL-15/sIL-15Rα is dependent on its avidity for MHC class I; thus, not all endogenous naïve CD8 T cells have the same potential to respond to IL-15 complex, highlighting important therapeutic implications. Finally, using a novel BAC-IL-15 EmGFP mouse model we describe the expression of IL-15 in the immune system, identifying novel IL-15 expressers and a previously unappreciated variation within dendritic cell populations. Furthermore, we note that IL-15 induction in response to viral infection is very quick and short-lived and surprisingly dependent on type I IFN. The data presented in this work furthers our understanding of general IL-15 biology and its potential as an immune-base therapeutic.
- …